Logo image of AZTR

AZITRA INC (AZTR) Stock Fundamental Analysis

NYSEARCA:AZTR - American Stock Exchange - US05479L2034 - Common Stock - Currency: USD

0.247  -0.02 (-7.8%)

Fundamental Rating

2

Taking everything into account, AZTR scores 2 out of 10 in our fundamental rating. AZTR was compared to 572 industry peers in the Biotechnology industry. The financial health of AZTR is average, but there are quite some concerns on its profitability. AZTR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AZTR had negative earnings in the past year.
AZTR had a negative operating cash flow in the past year.
AZTR Yearly Net Income VS EBIT VS OCF VS FCFAZTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of AZTR (-92.34%) is worse than 72.92% of its industry peers.
AZTR has a Return On Equity of -112.04%. This is comparable to the rest of the industry: AZTR outperforms 42.65% of its industry peers.
Industry RankSector Rank
ROA -92.34%
ROE -112.04%
ROIC N/A
ROA(3y)-174.1%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AZTR Yearly ROA, ROE, ROICAZTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 200 -200 400 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AZTR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AZTR Yearly Profit, Operating, Gross MarginsAZTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

4

2. Health

2.1 Basic Checks

AZTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AZTR has been reduced compared to 1 year ago.
The debt/assets ratio for AZTR has been reduced compared to a year ago.
AZTR Yearly Shares OutstandingAZTR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2M 4M 6M 8M 10M
AZTR Yearly Total Debt VS Total AssetsAZTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -10.16, we must say that AZTR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AZTR (-10.16) is worse than 74.69% of its industry peers.
AZTR has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
AZTR's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. AZTR outperforms 47.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.16
ROIC/WACCN/A
WACC8.63%
AZTR Yearly LT Debt VS Equity VS FCFAZTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

A Current Ratio of 5.58 indicates that AZTR has no problem at all paying its short term obligations.
AZTR has a Current ratio (5.58) which is comparable to the rest of the industry.
A Quick Ratio of 5.58 indicates that AZTR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.58, AZTR is in line with its industry, outperforming 59.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.58
Quick Ratio 5.58
AZTR Yearly Current Assets VS Current LiabilitesAZTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for AZTR have decreased strongly by -127.06% in the last year.
AZTR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -84.34%.
Measured over the past years, AZTR shows a quite strong growth in Revenue. The Revenue has been growing by 16.85% on average per year.
EPS 1Y (TTM)-127.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.09%
Revenue 1Y (TTM)-84.34%
Revenue growth 3Y16.85%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, AZTR will show a very strong growth in Earnings Per Share. The EPS will grow by 25.76% on average per year.
The Revenue is expected to grow by 73.27% on average over the next years. This is a very strong growth
EPS Next Y97.92%
EPS Next 2Y41.06%
EPS Next 3Y25.76%
EPS Next 5YN/A
Revenue Next Year-68.88%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y73.27%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AZTR Yearly Revenue VS EstimatesAZTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
AZTR Yearly EPS VS EstimatesAZTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AZTR. In the last year negative earnings were reported.
Also next year AZTR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AZTR Price Earnings VS Forward Price EarningsAZTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AZTR Per share dataAZTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

AZTR's earnings are expected to grow with 25.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.06%
EPS Next 3Y25.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AZTR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AZITRA INC

NYSEARCA:AZTR (1/27/2025, 11:48:14 AM)

0.247

-0.02 (-7.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners8.28%
Inst Owner Change0%
Ins Owners1.28%
Ins Owner Change0%
Market Cap1.88M
Analysts82.86
Price Target3.57 (1345.34%)
Short Float %7.31%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.41%
Min EPS beat(2)-3.52%
Max EPS beat(2)54.34%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-93.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)51.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-89.9%
Revenue NY rev (3m)-89.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.33
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.24
EV/EBITDA N/A
EPS(TTM)-7.48
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0.01
BVpS1.06
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -92.34%
ROE -112.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-174.1%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.67%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.58
Quick Ratio 5.58
Altman-Z -10.16
F-Score3
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)219.97%
Cap/Depr(5y)N/A
Cap/Sales(3y)149.56%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-127.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.09%
EPS Next Y97.92%
EPS Next 2Y41.06%
EPS Next 3Y25.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-84.34%
Revenue growth 3Y16.85%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-68.88%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y73.27%
EBIT growth 1Y-43.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.46%
OCF growth 3YN/A
OCF growth 5YN/A